Which closed-end funds own Regeneron Pharmaceuticals Inc?
8 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $50.4M. Security type: common equity. Country: United States. CUSIP 75886F107 · ISIN US75886F1075 · ticker REGN.
Holdings are historical filings (report dates Mar 31, 2026 – Jul 31, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| GAM General American Investors Co | U.S. Equity | 1.38% | $24.2M | 31,362 sh | $1.8B | 13.2% discount | Mar 31, 2026 |
| HQL abrdn Life Sciences Investors | Healthcare | 0.93% | $6.4M | 10,241 sh | $690M | 3.5% discount | Jun 30, 2026 |
| BME BlackRock Health Sciences Trust | Healthcare | 0.84% | $4.8M | 7,712 sh | $573M | 3.7% discount | Jun 30, 2026 |
| HQH abrdn Healthcare Investors | Healthcare | 0.52% | $7.1M | 11,310 sh | $1.4B | 7.5% discount | Jun 30, 2026 |
| USA Liberty All Star Equity Fund | U.S. Equity | 0.36% | $7.2M | 11,590 sh | $2B | 12.8% discount | Jun 30, 2026 |
| GRX Gabelli Healthcare & WellnessRx Trust | Healthcare | 0.30% | $695K | 1,115 sh | $228M | NAV unavailable | Jun 30, 2026 |
| GOF Guggenheim Strategic Opportunities Fund | Multi-Asset | 0.00% | $14.8K | 24 sh | $2.8B | 12.9% discount | May 29, 2026 |
| BRW Saba Capital Income & Opportunities Fund | U.S. Equity | -0.01% | $-45.8K | -60 sh | $351M | 17.8% discount | Jul 31, 2026 |
8 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: REGENERON PHARMACEUTICALS INC; Regeneron Pharmaceuticals, Inc..
Issuer-level search for “REGN” → · Compare two funds’ portfolios →